Sufficiently Pleaded Willful Infringement Claim and Inappropriate Royalty Base Calculation Result In Partial Reversal
Client Alert | 1 min read | 09.07.07
In Mitutoyo, Corp. et al. v. Central Purchasing, LLC (No. 06-1312, 1343, September 5, 2007) a Federal Circuit panel reverses-in-part a district court’s judgment dismissing the plaintiff’s claim of willful infringement and for including a second company’s sales figures in calculating the royalty base.
On appeal, the plaintiff is deemed to have sufficiently pleaded the willful infringement claim under its patent infringement count and because it had additionally provided details about the declaratory judgment suit filed by the defendant in 1995, thereby establishing that defendant had knowledge of the patent prior to 2002. Nothing in the plaintiff’s litigation conduct, notes the panel, evidenced an intent by plaintiff not to pursue its willful infringement claim; plaintiff had apprised the Court throughout the entire course of the litigation of its willful infringement claim and requested a trial on the issue.
With respect to the reasonable royalty calculation, the district court utilized both defendant’s and a second company’s sales of the accused products in calculating the royalty base. The Federal Circuit reverses as to the district court’s use of a royalty base that includes the second company’s sales figures, rather then defendant’s sales to that company. The panel notes that the two companies have a strong business relationship; however, they are independent corporate entities with different owners. No corporate relationship is found to exist between the second company and defendant, and there was no course of dealings or other evidence to suggest that defendant would have agreed to pay royalties on both company’s sales.
Insights
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage.
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance
Client Alert | 6 min read | 09.11.26
It’s LIVE: The Cyber Resilience Act Reporting Is Mandatory as of Today - 11 September 2026
Client Alert | 10 min read | 09.11.26
Mining, Indigenous Consultation Rights, and Investment Treaty Protection
